Marco Dal Molin, MD

Call

Advertisement

601 N Caroline St Fl 8
Baltimore, MD 21287
Marco Dal Molin, M.D., is a surgical oncologist that specializes in hepatobiliary, pancreatic and gastrointestinal surgical oncology at the Johns Hopkins Hospital. Dr. Dal Molin earned his medical degree at the University of Verona School of Medicine in Italy, followed by a general surgery residency at the University of Verona/Pancreas Institute. He completed a second general surgery residency at the University of Maryland in Baltimore, and a fellowship in Complex General Surgical Oncology at Johns Hopkins. Dr. Dal Molin received extensive postdoctoral research training at Johns Hopkins, including an NIH-funded T32 research fellowship prior to joining the surgical faculty. He specializes in the management of patients with pancreatic cancer, pancreatic cysts, as well as cancers of the liver, biliary tree and gastrointestinal tract. He is trained in traditional open and minimally invasive techniques to treating these cancers, using both laparoscopic and robotic approaches. Dr. Dal Molin’s research focuses on the development of liquid biopsies to improve the earlier detection and management of pancreatic cancer and pancreatic cysts. Another area of focus is the development of novel immunotherapies to treat pancreatic and hepatobiliary cancers.
Owner verified
See a problem?

You might also like

Jaishri Blakeley, MD
Internal medicine practitioners

Jaishri Blakeley, MD

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care.
United StatesMarylandBaltimoreMarco Dal Molin, MD

Yext

Advertisement